Drugs / Sobetirome
Sobetirome
Trials 2
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 11 trial | ||||||
| Phase 1 | NCT01787578 | Apr → Sep 2013 | X-linked cerebral adrenoleukodystrophy, adrenomyeloneuropathy | Thomas S. Scanlan | Withdrawn | No outcome recorded |
| Phase 1/21 trial | ||||||
| Phase 1/2 | NCT03196765 | Aug 2018 → Dec 2020 | X-linked cerebral adrenoleukodystrophy | NeuroVia, Inc. | Withdrawn | No outcome recorded Stop: Business |
Evidence & citations 6 cited values
Every value below carries the sentence it was read from. 3 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Sobetirome | ClinicalTrials.gov intervention name — accepted as the source's own label NCT01787578 ↗ |
| Known as | NV1205 | “Sobetirome (NV1205)” NCT03196765 ↗ |
| Known as | QRX-431 | ChEMBL registry synonym — accepted as the source's own label CHEMBL107400 ↗ |
| Known as | Sobetiroma | ChEMBL registry synonym — accepted as the source's own label CHEMBL107400 ↗ |
| Modality | Small molecule | — CHEMBL107400 ↗ |
| Route | Oral | “50 mcg or 100 mcg once-daily oral” NCT01787578 ↗ |